These in silico findings, together with great effects on SW-480 and HT-29 colon cancer cells, provide a foundation for further experimental validation and characterization of isorhamnetin’s interactions with target proteins, including CYP1A1, CYP1B1, P-gp, MRP1, and MRP5. The gene discussed is CYP1A1; the disease is colonic neoplasm.